This article was originally published on Microdose Psychedelic Insights and appears here with permission.
The innovative team at MagicMed, in pursuit of expanding their novel psychedelic derivative patent library (cleverly dubbed the “Psybrary™”), has formed a strategic partnership with the University of Calgary. The agreement gives the company access to the university’s cutting-edge research facilities and innovation capabilities.
In a recent article published by the University, MagicMed CEO Dr. Joseph Tucker had this to say about the exciting developments: “There’s millions of dollars’ worth of equipment, not to mention the world-class intellectual expertise, all of which is accessible because of this ongoing, symbiotic relationship…”
Robust Research Efforts Will Pave the Way Forward for Psychedelics
The MagicMed team’s dedication to strong research and development efforts has positioned them to be powerful players in the emerging psychedelic medicine space. Indeed, the powerhouse team at Compass Pathways is currently leading the way in psychedelic research and development spending–a promising sign. As psychedelic compounds transition out of the cultural shadows of prohibition and into mainstream medicine, the value of high fidelity clinical trials and robust research efforts cannot be overstated.
Advancing Psychedelic Medicine Through Powerful & Patentable Derivatives
The traditional psychedelic compounds, such as LSD, psilocybin and …